Karin Langenberg-Ververgaert: Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines
Karin Langenberg-Ververgaert, Vice president at Society for Functional Precision Medicine, shared her recent article on LinkedIn:
“Proud to present the work of the lab of Jan Molenaar and collaborators at the Prinses Máxima Centre and DKFZ German Cancer Research Center, demonstrating utility of neuroblastoma models and drug sensitivity testing within the iTHER precision medicine program, funded by Stichting Kinderen Kankervrij (KiKa), ZonMw, European Research Council (ERC), NWO (Dutch Research Council), and many others.
Available now at R2 Genomics Analysis and Visualization Platform!
We are extremely grateful to all patients and their families who participated in this trial.
Our mission: to cure every child with cancer, with optimal quality of life.”
Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine.
Authors: Karin P.S. Langenberg, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023